The Global Hemophilia Treatment Market size is anticipated to grow at a CAGR of 6.9% during the forecast period. Hemophilia is expected to be a complex disorder. It’s a mostly inherited genetic disease that impairs the body's ability to form blood clots, a process needed to prevent bleeding. The simplest thanks to treating hemophilia are to exchange the missing blood coagulation factor in order that the blood can clot properly.
Get free sample copy of this report @ https://bit.ly/3kUMxKy
Key Developments in Hemophilia Treatment Market:
- In March 2019, Gene therapy for hemophilia is starting to come of age and promises to transform the way patients with this rare blood disease are treated.
- In February 2019, the FDA has approved the Biologics License Application for Novo Nordisk’s long-acting factor VIII replacement treatment for adults and children with hemophilia A.
The key leading players in the market include Baxter International, Inc., Grifols SA, CSL Ltd, Octapharma AG, Novo Nordisk, Kedrion, Pfizer, Inc., Bayer AG, Biogen Idec, Inc., and Hospira, Inc.
Get free PDF of this report @ https://bit.ly/3F5fMlV
The global biologics safety testing market is expected to reach USD 4.90 Billion by 2022 from USD 2.75 Billion in 2017, at a CAGR of 12.2% during forecast period.
The major factors driving the growth of this market are the growth in pharmaceutical & biotechnology industry driven by government support, the positive trend of R investment in the life science sector, increasing number of drug launches, and high incidence & large economic burden of chronic diseases.
In the coming years, emerging markets and increasing pharmaceutical outsourcing are expected to offer growth opportunities for players in the biologics safety testing market.Market Dynamics :Pharmaceutical and biotechnology companies are the largest end users in the biologics safety testing market.
Biologics safety testing is carried out at all levels of manufacturing to minimize the risk of product contamination in these industries.
According to the International Trade Administration, the global pharmaceuticals market is projected to grow from USD 1 trillion in 2015 to USD 1.3 trillion by 2020, at a CAGR of 4.9%.Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144The kits & reagents segment is projected to register the highest during the forecast period.
The growth of this market segment is driven by repeat purchase of kits and reagents as compared to instruments and increasing adoption of kit-based testing.Vaccine and Therapeutics Development segment is projected to register a higher CAGR during the forecast period.
The Global Asthma Therapeutics Market is anticipated to grow at a CAGR of 5.2% during the forecast period and reach USD 22.4 billion by 2028.
Asthma is a lung disorder wherein inflammation causes the bronchi to swell and narrow down the airways resulting in breathing difficulties that may be a mild or life-threatening inconsiderable number of cases.
Get free sample copy of this report @ https://bit.ly/3oc843h Key Developments in Asthma Therapeutics Market:In November 2017, U.S. Food and Drug Administration (USFDA) announced the approval of Fasenra (benralizumab).
It is used for the treatment and management of severe asthma inpatient.
Fasenra is a new precision biologic, intended to improve the condition of severe asthma patients.In February 2018, Teva Pharmaceutical Industries Ltd. launched its new QVAR RediHaler (Beclomethasone Dipropionate HFA) Inhalation Aerosol in the U.S.
It is used for the treatment and control of asthma.
According to the new market research report “Regenerative Medicine Market by Type [Cell-Based Immunotherapy & Cell Therapy (Allogeneic & Autologous Products), Tissue Engineering, Gene Therapy], Applications (Wounds & Dermal, Musculoskeletal, Oncology), Region — Global Forecast to 2024”, published by MarketsandMarkets™, the Regenerative Medicine Market is expected to reach USD 38.7 billion by 2024 from USD 13.3 billion in 2019, at a CAGR of 23.8%.Growth in this market is largely driven by the introduction of Cures Act for regenerative medicine by FDA, increased funding for regenerative medicine research, development of CAR-T cell therapies and increasing demand for regenerative medicine for the treatment of cancer, orthopedic disorders, and chronic wounds among others.
Cell-based immunotherapy & cell therapy products segment dominated the Regenerative Medicine Market in 2019.On the basis of type, the Regenerative Medicine Market is classified into cell-based immunotherapy & cell therapy products, gene therapy products, and tissue-engineered products.
The cell-based immunotherapy & cell therapy products segment accounted for the largest market share in 2019 owing to increasing demand for cell-based immunotherapies, the establishment of cures act by FDA to streamline the regenerative medicine approval are the major factors driving the growth of this market segment.Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65442579Browse and in-depth TOC on “Regenerative Medicine Market”76 — Tables29 — Figures107 — PagesMusculoskeletal disorders applications segment likely to dominate the market in 2019.On the basis of application, the Regenerative Medicine Market is categorized into musculoskeletal disorders, wound care, oncology, ocular disorders, diabetes, and other applications.
In 2019, the musculoskeletal disorders segment accounted for the largest market share.
The large share of this segment can mainly be attributed to the rising incidence rate of orthopedic diseases with a rising geriatric population.North America anticipated accounting for the largest share of the Regenerative Medicine Market in 2019.The Regenerative Medicine Market in North America is expected to account for the largest share globally and also grow at a faster rate during the forecast period.
Surging research activities in the field of regenerative medicine, the introduction of CAR-T cell therapies and growing awareness of personalized medicine have also resulted in the establishment of stem cell banking and tissue engineering.Read a Press Release on “Regenerative Medicine Market”:https://www.marketsandmarkets.com/PressReleases/regenerative-medicine.aspThe major players in this market are Kite Pharma (US), Novartis (Switzerland), Vericel Corporation (US), Integra LifeSciences (US), Wright Medical (US), MiMedx (US), Osiris Therapeutics (US), Stryker Corporation (US), and Spark Therapeutics (US).
The major factors driving the CRISPR technology market include the rising funding from government and private organizations and the high adoption of CRISPR technology.The CRISPR Technology marketis expected to grow from USD 562 million in 2018 to USD 1,715 million by 2023, at a CAGR of 25% during the forecast period.The CRISPR services market is segmented into gRNA design and vector construction, cell line engineering, screening services, and other CRISPR services (mediated transcriptome editing and epigenome editing services).
The cell line engineering services segment is expected to grow at the highest rate.Download PDF Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134401204The biomedical applications segment is projected to be the fastest-growing segment of the market, by application, during the forecast period.
Developments in gene therapy, drug discovery, and diagnostics, due to the application of CRISPR, are driving the growth of this biomedical segment.
Many companies have also invested in drug discovery and gene therapy companies that are using CRISPR technology.View complete press release:-https://www.marketsandmarkets.com/PressReleases/crispr-technology.asp
The global Facial Injectable Market size to witness a CAGR Exceeding 28.1% over the forecast period (2019-2025).
Facial injectable market is projected to grow rapidly due to rising demand for cosmetic alterations to improve one’s own appearance and growing disposable income of consumers in developed economies.
The increasing commercialization of skin care and beauty products in the developed countries has led to the emergence of a culture that normalizes and even glorifies attractive appearance, leading to a growing demand from the facial injectables market.
geriatric population in developed economic is increasing at a steady rate and is likely to become a leading spender on beauty products in the coming years.
Moreover, stem cell technology, gene therapy, and targeted delivery of nutrients using biotechnology are anticipated to open gates for anti-aging drugs.
Development of biomarkers for physiochemical modification in the human body provides prospects for the market.
